also known as 'The Suicide Disease' is a chronic pain condition that affects the trigeminal or 5th cranial nerve, one of the most widely distributed nerves in the head.
While the most common cause of cranial neuralgia
is trigeminal neuralgia
, limited data are available on the incidence of NIN.
Neucourse is a single phase 3, double-blind, placebo-controlled and 14-week study evaluating mirogabalin in 765 post-herpetic neuralgia
Asian patients aged 20 years or older across 200 centres in Japan, Taiwan, Korea, Singapore, Malaysia and Thailand.
(TN) is one of the most common causes of facial pain, with the annual incidence of 4 to 13 per 100 000 people and increasing gradually with age (1,2).
was seen in 40 (80%) patients with age more than 50 years.
Material and Methods: Fifty patients with post herpetic neuralgia
(PHN), 10 patients with trigeminal neuralgia
and 20 patients with nerve entrapment pain were included in the study.
Objective: To dtermine the outcome of trigeminal nerve compression technique (TGNC) treatment for the idiopathic trigeminal neuralgia
without decompressing the nerve compressed by the offending vessel.
Superior laryngeal (SL) neuralgia
is paroxysmal pain above the thyrohyoid membrane.
USPRwire, Wed Jan 13 2016] Global Markets Direct's, 'Postherpetic Neuralgia
- Pipeline Review, H2 2015', provides an overview of the Postherpetic Neuralgia
's therapeutic pipeline.
Global Markets Direct's, 'Trigeminal Neuralgia
- Pipeline Review, H2 2015', provides an overview of the Trigeminal Neuralgia
's therapeutic pipeline.
To the Editor: Occipital neuralgia
(ON) is the third most common headache syndrome following migraine and tension-type headache.
M2 EQUITYBITES-August 11, 2015-Mylan unveils generic Lidoderm Patch for pain associated with post-herpetic neuralgia
in the US
Of all the neuralgias
in the maxillofacial region, Post Herpetic Neuralgia
is infrequent but is demanding in the process of cure and invites debate.
is defined according to guidelines provided by the International Headache Society (IHS).
The phase 3 clinical program across Asia includes the REDUCER (An Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopathic pain followed by a 52-week open-label extension) study and the NEUCOURSE (An AsiaN, phasE 3, mUltiCenter, randomized, dOUble-blind, placebo-contRolled 14-week study of DS-5565 in patientS with postherpetic neuralgia
followed by a 52-week open-label Extension) study which will evaluate investigational mirogabalin for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia